Trial Profile
Bevacizumab, dacarbazine and interferon alfa-2a combination as a first-line therapy in patients with locally advancing or metastatic melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Dacarbazine (Primary) ; Interferon alpha-2a (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Apr 2009 Planned number of patients changed from 40 to 27 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.